Nevro Corp.

DB:1N7 Stock Report

Market Cap: €162.6m

Nevro Valuation

Is 1N7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1N7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1N7's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1N7's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1N7?

Key metric: As 1N7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1N7. This is calculated by dividing 1N7's market cap by their current revenue.
What is 1N7's PS Ratio?
PS Ratio0.4x
SalesUS$419.15m
Market CapUS$169.37m

Price to Sales Ratio vs Peers

How does 1N7's PS Ratio compare to its peers?

The above table shows the PS ratio for 1N7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
PUS PULSION Medical Systems
3.8xn/a€134.4m
SBS Stratec
1.3x7.7%€321.5m
DRW3 Drägerwerk KGaA
0.2x4.2%€796.1m
EUZ Eckert & Ziegler
3x6.3%€831.3m
1N7 Nevro
0.4x2.5%€169.4m

Price-To-Sales vs Peers: 1N7 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does 1N7's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$828.96m
PHH2 Paul Hartmann
0.3xn/aUS$773.00m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
1N7 0.4xIndustry Avg. 3.4xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1N7 is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is 1N7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1N7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: 1N7 is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1N7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.10
€6.64
+61.8%
32.9%€12.24€3.77n/a11
Nov ’25€4.84
€6.64
+37.2%
31.7%€11.94€3.67n/a11
Oct ’25€4.92
€6.86
+39.4%
29.3%€11.74€3.61n/a11
Sep ’25€5.65
€6.78
+20.0%
29.0%€11.76€3.62n/a12
Aug ’25€9.10
€12.92
+42.0%
53.6%€36.69€7.52n/a14
Jul ’25€7.80
€13.68
+75.3%
47.9%€36.96€8.32n/a15
Jun ’25€8.40
€13.68
+62.8%
47.9%€36.96€8.32n/a15
May ’25€10.60
€16.62
+56.8%
35.2%€37.49€13.12n/a15
Apr ’25€13.20
€17.93
+35.8%
30.1%€36.96€12.94n/a15
Mar ’25€13.40
€17.93
+33.8%
30.1%€36.96€12.94n/a15
Feb ’25€15.20
€19.75
+29.9%
30.5%€36.85€13.82n/a16
Jan ’25€19.80
€19.34
-2.3%
32.9%€36.36€11.82n/a16
Dec ’24€15.80
€18.74
+18.6%
38.2%€37.30€12.12n/a16
Nov ’24€13.60
€24.33
+78.9%
40.1%€54.11€16.14€4.8415
Oct ’24€18.50
€26.18
+41.5%
33.4%€52.55€17.52€4.9215
Sep ’24€18.40
€26.18
+42.3%
33.4%€52.55€17.52€5.6515
Aug ’24€22.60
€32.02
+41.7%
41.0%€66.96€21.43€9.1015
Jul ’24€23.40
€34.42
+47.1%
39.3%€68.72€21.99€7.8014
Jun ’24€25.60
€38.43
+50.1%
35.4%€71.11€27.14€8.4014
May ’24€27.40
€38.87
+41.9%
35.0%€68.97€28.13€10.6012
Apr ’24€32.60
€42.37
+30.0%
31.1%€70.76€31.13€13.2011
Mar ’24€29.60
€42.37
+43.1%
31.1%€70.76€31.13€13.4011
Feb ’24€33.60
€41.16
+22.5%
28.6%€68.87€30.30€15.2011
Jan ’24€37.20
€45.21
+21.5%
26.5%€70.64€29.20€19.8011
Dec ’23€44.60
€46.59
+4.5%
26.1%€72.65€30.03€15.8011
Nov ’23€38.60
€53.65
+39.0%
28.0%€87.05€31.38€13.6011

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-8.8%

1Y

-37.3%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-5.5%

1Y

18.9%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%